Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 99 USD 12.08% Market Closed
Market Cap: 2.1B USD

Intrinsic Value

CYTH doesn't have a meaningful market cap.

The intrinsic value of one CYTH stock under the Base Case scenario is 641.3 USD. Compared to the current market price of 99 USD, Cyclo Therapeutics Inc is Undervalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYTH Intrinsic Value
641.3 USD
Undervaluation 85%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Cyclo Therapeutics Inc

What is Valuation History?
Compare CYTH to

Fundamental Analysis

Cyclo Therapeutics Inc
NASDAQ:CYTH
US
Biotechnology
Market Cap
2.1B USD
IPO
Feb 27, 2004
US
Biotechnology
Market Cap
2.1B USD
IPO
Feb 27, 2004
Price
$false
EPS
$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CYTH?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Cyclo Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cyclo Therapeutics Inc

Current Assets 3.3m
Cash & Short-Term Investments 928k
Receivables 187.7k
Other Current Assets 2.1m
Non-Current Assets 2m
PP&E 46.6k
Other Non-Current Assets 2m
Efficiency

Free Cash Flow Analysis
Cyclo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Cyclo Therapeutics Inc

Revenue
870.7k USD
Cost of Revenue
-76.2k USD
Gross Profit
794.5k USD
Operating Expenses
-25.5m USD
Operating Income
-24.7m USD
Other Expenses
-122.8k USD
Net Income
-24.8m USD
Fundamental Scores

CYTH Profitability Score
Profitability Due Diligence

Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

44/100
Profitability
Score

Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

CYTH Solvency Score
Solvency Due Diligence

Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Positive Net Debt
37/100
Solvency
Score

Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTH Price Targets Summary
Cyclo Therapeutics Inc

There are no price targets for CYTH.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Cyclo Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CYTH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CYTH Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CYTH stock?

The intrinsic value of one CYTH stock under the Base Case scenario is 641.3 USD.

Is CYTH stock undervalued or overvalued?

Compared to the current market price of 99 USD, Cyclo Therapeutics Inc is Undervalued by 85%.

Back to Top